Efficacy and safety of anti-LAG-3 IBI110 in combination with sintilimab and chemotherapy for advanced squamous non-small cell lung cancer: a randomized phase II study
抗LAG-3抗体IBI110联合信迪利单抗和化疗治疗晚期鳞状非小细胞肺癌的疗效和安全性:一项随机II期研究
期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-026-04299-x
Wang, Qianyi; Xiong, Anwen; Mao, Chenyu; Wang, Wenxiang; Cui, Jiuwei; Fang, Jian; Zhuang, Wu; Yang, Kunyu; Zuo, Wei; Yang, Jun; Ye, Lika; Zhang, Zhiye; Sheng, Zengmei; Liu, Zhe; Wang, Donglin; Du, Xiaobo; Yi, Tienan; Long, Sixiang; Xu, Nong; Zhou, Caicun